Intrinsic value of Seres Therapeutics, Inc. - MCRB

Previous Close

$6.22

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$6.22

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of MCRB stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  45
  69
  104
  150
  212
  291
  391
  513
  661
  834
  1,036
  1,267
  1,527
  1,817
  2,136
  2,485
  2,863
  3,268
  3,702
  4,162
  4,648
  5,160
  5,698
  6,260
  6,848
  7,461
  8,099
  8,763
  9,453
  10,171
Variable operating expenses, $m
  173
  267
  399
  579
  817
  1,124
  1,508
  1,980
  2,548
  3,219
  3,997
  4,886
  5,890
  7,008
  8,240
  9,585
  11,041
  12,606
  14,277
  16,051
  17,927
  19,902
  21,975
  24,145
  26,412
  28,775
  31,237
  33,798
  36,460
  39,228
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  173
  267
  399
  579
  817
  1,124
  1,508
  1,980
  2,548
  3,219
  3,997
  4,886
  5,890
  7,008
  8,240
  9,585
  11,041
  12,606
  14,277
  16,051
  17,927
  19,902
  21,975
  24,145
  26,412
  28,775
  31,237
  33,798
  36,460
  39,228
Operating income, $m
  -128
  -198
  -296
  -429
  -605
  -832
  -1,117
  -1,467
  -1,888
  -2,384
  -2,961
  -3,620
  -4,363
  -5,191
  -6,103
  -7,100
  -8,178
  -9,337
  -10,575
  -11,890
  -13,279
  -14,742
  -16,278
  -17,885
  -19,564
  -21,315
  -23,138
  -25,035
  -27,007
  -29,057
EBITDA, $m
  -119
  -183
  -274
  -397
  -561
  -771
  -1,034
  -1,358
  -1,748
  -2,208
  -2,741
  -3,351
  -4,040
  -4,806
  -5,651
  -6,574
  -7,573
  -8,646
  -9,792
  -11,009
  -12,296
  -13,650
  -15,072
  -16,561
  -18,115
  -19,736
  -21,424
  -23,181
  -25,007
  -26,905
Interest expense (income), $m
  0
  0
  -3
  0
  5
  11
  19
  30
  43
  59
  79
  102
  128
  159
  194
  232
  275
  321
  371
  425
  482
  544
  608
  676
  747
  822
  900
  982
  1,066
  1,154
  1,246
Earnings before tax, $m
  -128
  -195
  -296
  -434
  -616
  -851
  -1,147
  -1,510
  -1,947
  -2,463
  -3,062
  -3,748
  -4,522
  -5,385
  -6,336
  -7,374
  -8,499
  -9,709
  -11,000
  -12,372
  -13,823
  -15,350
  -16,954
  -18,633
  -20,386
  -22,215
  -24,120
  -26,101
  -28,162
  -30,303
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -128
  -195
  -296
  -434
  -616
  -851
  -1,147
  -1,510
  -1,947
  -2,463
  -3,062
  -3,748
  -4,522
  -5,385
  -6,336
  -7,374
  -8,499
  -9,709
  -11,000
  -12,372
  -13,823
  -15,350
  -16,954
  -18,633
  -20,386
  -22,215
  -24,120
  -26,101
  -28,162
  -30,303

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  122
  189
  283
  410
  579
  796
  1,068
  1,403
  1,805
  2,280
  2,831
  3,461
  4,172
  4,964
  5,837
  6,790
  7,821
  8,930
  10,113
  11,370
  12,699
  14,099
  15,567
  17,104
  18,710
  20,384
  22,128
  23,942
  25,828
  27,788
Adjusted assets (=assets-cash), $m
  122
  189
  283
  410
  579
  796
  1,068
  1,403
  1,805
  2,280
  2,831
  3,461
  4,172
  4,964
  5,837
  6,790
  7,821
  8,930
  10,113
  11,370
  12,699
  14,099
  15,567
  17,104
  18,710
  20,384
  22,128
  23,942
  25,828
  27,788
Revenue / Adjusted assets
  0.369
  0.365
  0.367
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
  0.366
Average production assets, $m
  47
  73
  110
  159
  224
  308
  414
  543
  699
  883
  1,096
  1,340
  1,616
  1,922
  2,260
  2,629
  3,029
  3,458
  3,916
  4,403
  4,918
  5,459
  6,028
  6,623
  7,245
  7,893
  8,568
  9,271
  10,001
  10,760
Working capital, $m
  -56
  -87
  -131
  -189
  -267
  -367
  -493
  -647
  -833
  -1,052
  -1,307
  -1,598
  -1,926
  -2,291
  -2,694
  -3,134
  -3,610
  -4,121
  -4,668
  -5,248
  -5,861
  -6,507
  -7,185
  -7,894
  -8,635
  -9,408
  -10,212
  -11,050
  -11,920
  -12,825
Total debt, $m
  -58
  2
  86
  201
  353
  548
  793
  1,094
  1,456
  1,883
  2,380
  2,947
  3,587
  4,299
  5,085
  5,942
  6,871
  7,868
  8,934
  10,065
  11,261
  12,520
  13,842
  15,225
  16,670
  18,177
  19,746
  21,379
  23,077
  24,841
Total liabilities, $m
  110
  170
  255
  369
  521
  716
  962
  1,263
  1,625
  2,052
  2,548
  3,115
  3,755
  4,468
  5,253
  6,111
  7,039
  8,037
  9,102
  10,233
  11,429
  12,689
  14,010
  15,394
  16,839
  18,346
  19,915
  21,548
  23,245
  25,010
Total equity, $m
  12
  19
  28
  41
  58
  80
  107
  140
  181
  228
  283
  346
  417
  496
  584
  679
  782
  893
  1,011
  1,137
  1,270
  1,410
  1,557
  1,710
  1,871
  2,038
  2,213
  2,394
  2,583
  2,779
Total liabilities and equity, $m
  122
  189
  283
  410
  579
  796
  1,069
  1,403
  1,806
  2,280
  2,831
  3,461
  4,172
  4,964
  5,837
  6,790
  7,821
  8,930
  10,113
  11,370
  12,699
  14,099
  15,567
  17,104
  18,710
  20,384
  22,128
  23,942
  25,828
  27,789
Debt-to-equity ratio
  -4.770
  0.090
  3.040
  4.890
  6.090
  6.880
  7.420
  7.800
  8.070
  8.260
  8.400
  8.510
  8.600
  8.660
  8.710
  8.750
  8.780
  8.810
  8.830
  8.850
  8.870
  8.880
  8.890
  8.900
  8.910
  8.920
  8.920
  8.930
  8.930
  8.940
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -128
  -195
  -296
  -434
  -616
  -851
  -1,147
  -1,510
  -1,947
  -2,463
  -3,062
  -3,748
  -4,522
  -5,385
  -6,336
  -7,374
  -8,499
  -9,709
  -11,000
  -12,372
  -13,823
  -15,350
  -16,954
  -18,633
  -20,386
  -22,215
  -24,120
  -26,101
  -28,162
  -30,303
Depreciation, amort., depletion, $m
  9
  15
  22
  32
  45
  62
  83
  109
  140
  177
  219
  268
  323
  384
  452
  526
  606
  692
  783
  881
  984
  1,092
  1,206
  1,325
  1,449
  1,579
  1,714
  1,854
  2,000
  2,152
Funds from operations, $m
  -119
  -180
  -274
  -402
  -571
  -790
  -1,064
  -1,401
  -1,807
  -2,286
  -2,843
  -3,480
  -4,199
  -5,000
  -5,884
  -6,849
  -7,894
  -9,017
  -10,217
  -11,491
  -12,839
  -14,258
  -15,748
  -17,308
  -18,937
  -20,636
  -22,406
  -24,247
  -26,161
  -28,151
Change in working capital, $m
  -21
  -31
  -43
  -59
  -78
  -100
  -126
  -154
  -186
  -219
  -254
  -291
  -328
  -365
  -403
  -440
  -476
  -512
  -546
  -580
  -613
  -646
  -678
  -709
  -741
  -773
  -805
  -837
  -871
  -905
Cash from operations, $m
  -97
  -149
  -231
  -343
  -494
  -690
  -938
  -1,247
  -1,621
  -2,067
  -2,589
  -3,189
  -3,871
  -4,635
  -5,481
  -6,409
  -7,418
  -8,505
  -9,671
  -10,911
  -12,226
  -13,613
  -15,071
  -16,599
  -18,196
  -19,864
  -21,601
  -23,410
  -25,291
  -27,247
Maintenance CAPEX, $m
  -6
  -9
  -15
  -22
  -32
  -45
  -62
  -83
  -109
  -140
  -177
  -219
  -268
  -323
  -384
  -452
  -526
  -606
  -692
  -783
  -881
  -984
  -1,092
  -1,206
  -1,325
  -1,449
  -1,579
  -1,714
  -1,854
  -2,000
New CAPEX, $m
  -18
  -26
  -36
  -49
  -65
  -84
  -105
  -130
  -156
  -184
  -213
  -244
  -275
  -307
  -338
  -369
  -399
  -429
  -458
  -487
  -515
  -542
  -569
  -595
  -622
  -648
  -675
  -702
  -730
  -759
Cash from investing activities, $m
  -24
  -35
  -51
  -71
  -97
  -129
  -167
  -213
  -265
  -324
  -390
  -463
  -543
  -630
  -722
  -821
  -925
  -1,035
  -1,150
  -1,270
  -1,396
  -1,526
  -1,661
  -1,801
  -1,947
  -2,097
  -2,254
  -2,416
  -2,584
  -2,759
Free cash flow, $m
  -121
  -184
  -282
  -414
  -591
  -818
  -1,105
  -1,459
  -1,886
  -2,391
  -2,979
  -3,652
  -4,414
  -5,264
  -6,203
  -7,230
  -8,343
  -9,540
  -10,820
  -12,181
  -13,621
  -15,138
  -16,731
  -18,399
  -20,143
  -21,961
  -23,855
  -25,826
  -27,876
  -30,006
Issuance/(repayment) of debt, $m
  -58
  60
  84
  115
  152
  195
  245
  301
  362
  427
  496
  567
  640
  713
  786
  858
  928
  998
  1,065
  1,131
  1,196
  1,259
  1,322
  1,383
  1,445
  1,507
  1,569
  1,633
  1,698
  1,764
Issuance/(repurchase) of shares, $m
  232
  201
  305
  446
  633
  873
  1,174
  1,543
  1,987
  2,510
  3,117
  3,811
  4,593
  5,464
  6,423
  7,470
  8,602
  9,819
  11,118
  12,498
  13,956
  15,490
  17,101
  18,786
  20,547
  22,382
  24,294
  26,283
  28,350
  30,499
Cash from financing (excl. dividends), $m  
  174
  261
  389
  561
  785
  1,068
  1,419
  1,844
  2,349
  2,937
  3,613
  4,378
  5,233
  6,177
  7,209
  8,328
  9,530
  10,817
  12,183
  13,629
  15,152
  16,749
  18,423
  20,169
  21,992
  23,889
  25,863
  27,916
  30,048
  32,263
Total cash flow (excl. dividends), $m
  53
  77
  108
  147
  194
  250
  314
  385
  463
  547
  635
  726
  819
  912
  1,005
  1,097
  1,188
  1,277
  1,363
  1,448
  1,530
  1,612
  1,691
  1,770
  1,849
  1,928
  2,008
  2,089
  2,172
  2,258
Retained Cash Flow (-), $m
  -232
  -201
  -305
  -446
  -633
  -873
  -1,174
  -1,543
  -1,987
  -2,510
  -3,117
  -3,811
  -4,593
  -5,464
  -6,423
  -7,470
  -8,602
  -9,819
  -11,118
  -12,498
  -13,956
  -15,490
  -17,101
  -18,786
  -20,547
  -22,382
  -24,294
  -26,283
  -28,350
  -30,499
Prev. year cash balance distribution, $m
  44
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -135
  -124
  -197
  -300
  -439
  -623
  -860
  -1,158
  -1,524
  -1,963
  -2,482
  -3,085
  -3,774
  -4,552
  -5,418
  -6,372
  -7,414
  -8,543
  -9,755
  -11,050
  -12,425
  -13,879
  -15,409
  -17,016
  -18,698
  -20,454
  -22,286
  -24,193
  -26,178
  -28,242
Discount rate, %
  5.60
  5.88
  6.17
  6.48
  6.81
  7.15
  7.50
  7.88
  8.27
  8.69
  9.12
  9.58
  10.06
  10.56
  11.09
  11.64
  12.22
  12.84
  13.48
  14.15
  14.86
  15.60
  16.38
  17.20
  18.06
  18.96
  19.91
  20.91
  21.95
  23.05
PV of cash for distribution, $m
  -128
  -111
  -165
  -233
  -316
  -412
  -518
  -631
  -745
  -853
  -950
  -1,029
  -1,086
  -1,116
  -1,119
  -1,094
  -1,044
  -972
  -883
  -783
  -677
  -572
  -470
  -377
  -295
  -224
  -165
  -119
  -83
  -56
Current shareholders' claim on cash, %
  50.0
  2.9
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

FINANCIAL RATIOS  of  Seres Therapeutics, Inc. (MCRB)

Valuation Ratios
P/E Ratio -2.7
Price to Sales 11.4
Price to Book 1.9
Price to Tangible Book
Price to Cash Flow 5.7
Price to Free Cash Flow 10.9
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 425%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 8.3%
Total Debt to Equity 8.3%
Interest Coverage 0
Management Effectiveness
Return On Assets -37.6%
Ret/ On Assets - 3 Yr. Avg. -33%
Return On Total Capital -52.6%
Ret/ On T. Cap. - 3 Yr. Avg. -39.1%
Return On Equity -54.4%
Return On Equity - 3 Yr. Avg. -40.2%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -400%
EBITDA Margin - 3 Yr. Avg. -133.3%
Operating Margin -422.7%
Oper. Margin - 3 Yr. Avg. -140.9%
Pre-Tax Margin -418.2%
Pre-Tax Margin - 3 Yr. Avg. -139.4%
Net Profit Margin -418.2%
Net Profit Margin - 3 Yr. Avg. -139.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

MCRB stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MCRB stock intrinsic value calculation we used $28 million for the last fiscal year's total revenue generated by Seres Therapeutics, Inc.. The default revenue input number comes from 0001 income statement of Seres Therapeutics, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MCRB stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.6%, whose default value for MCRB is calculated based on our internal credit rating of Seres Therapeutics, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Seres Therapeutics, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MCRB stock the variable cost ratio is equal to 385.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MCRB stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Seres Therapeutics, Inc..

Corporate tax rate of 27% is the nominal tax rate for Seres Therapeutics, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MCRB stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MCRB are equal to 105.8%.

Life of production assets of 3.8 years is the average useful life of capital assets used in Seres Therapeutics, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MCRB is equal to -126.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-48.045 million for Seres Therapeutics, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 41.049 million for Seres Therapeutics, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Seres Therapeutics, Inc. at the current share price and the inputted number of shares is $0.3 billion.

RELATED COMPANIES Price Int.Val. Rating
NKTR Nektar Therape 32.17 44.57  buy
PGNX Progenics Phar 4.33 13.32  str.buy
KDMN Kadmon Holding 2.77 0.29  str.sell

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.